Loading stock data…
$5.98+0.09 (+1.53%)
Bausch Health Companies Inc.
Bausch Health Companies Inc. in the Healthcare sector is trading at $5.98 with a market capitalization of $2.3B. Wall Street consensus targets $7.50 (5 analysts), implying a +25.4% move over the next 12 months. The stock is currently 25% below its 52-week high of $8.00, remaining 4.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.85B↑ | $2.52B↓ | $2.80B↑ | $2.68B↑ | $2.53B |
| Gross Profit | $2.08B↑ | $1.79B↓ | $2.00B↑ | $1.93B↑ | $1.77B |
| Operating Income | $775.00M↑ | $521.00M↓ | $829.00M↑ | $636.00M↑ | $457.00M |
| Net Income | $258.00M↑ | -$1.42B↓ | -$112.00M↓ | $179.00M↑ | $148.00M |
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, an...